Sunday, May 19, 2013

[MCM] FDA winks at mammoth fraud by Indian drug giant making Lipitor


The epic inside story of fraud at a generic Lipitor giant
Dear Friends and Colleagues, 
I am happy to share with you my most recent story, Dirty Medicine: The epic inside story of long-term criminal fraud at Ranbaxy, the Indian drug company that makes generic Lipitor for millions of Americans.  It is up on Fortune's website this morning.  
The article was years in the making. It yields the first comprehensive picture of how one under-policed and far-flung generics company operated. It is not a tale of cutting corners or lax manufacturing practices but one of outright fraud, in which the company knowingly sold substandard drugs around the world—including in the U.S.—while working to deceive regulators. It is based on more than 1,000 confidential Ranbaxy documents, including internal reports, memos, e-mails, hundreds of pages of FDA documents obtained through Freedom of Information Act requests, and court records. Fortune interviewed more than a dozen former and current employees, as well as 40 scientists, public health experts, patient advocates, congressional investigators, and regulators.

Hope you enjoy. Katherine

No comments:

Post a Comment